Project Report for Pharmaceutical Business
Starting a pharmaceutical manufacturing facility involves more than just funding and machinery planning. Compliance with regulatory regulations, particularly Revised Schedule M criteria, is an important consideration for approval. A well-written company plan should address infrastructure, financial feasibility, and production processes. Sharda Associates, a Bhopal-based CA and financial consultancy firm, provides CA-certified project reports to entrepreneurs and MSMEs in industrial sectors.
Get free Sample
What Changed in 2026 — And Why It Matters for New Entrants
Schedule M is the section of India’s Drugs and Cosmetics criteria that specifies Good Manufacturing Practice (GMP) standards, which are the criteria for plant design, documentation, equipment qualification, and quality systems that all drug manufacturers must follow.
In 2023, the government published a Revised Schedule M that brings Indian regulations far closer to WHO-GMP (the World Health Organization’s worldwide manufacturing standard), and after an extended compliance deadline, it became enforceable for all firms, including MSMEs, in January 2026.
This is a genuine, present shift, not mere regulatory noise. Industry sources report that non-compliant facilities may face show-cause notices, license suspension, or product recall orders, with remediation costs ranging from ₹2-10 crore per facility if designed incorrectly from the start. State drug control departments have already begun active inspections against the revised standard.
For a new entrant, the practical implication is straightforward: your facility layout, HVAC (air handling) system, water system, and documentation processes must be designed to Revised Schedule M criteria from the start, rather than retrofitted after a failed inspection.
Why This Industry Is Still Worth Entering
Despite the increased compliance bar, the underlying opportunity remains significant. India is the world’s third-largest pharmaceutical producer by volume and a key source of generic medications, with an estimated domestic market of USD 130 billion and yearly exports topping USD 30 billion. Currently, less than 25% of MSME pharma firms have WHO-GMP certification, which means that compliant new entrants have a real potential to access institutional tenders, export markets, and larger contract manufacturing agreements that noncompliant competitors cannot.
Licenses and Approvals You'll Need
Requirement | What It Involves |
Manufacturing License | Issued by your State Drug Control Department (State FDA) under the Drugs and Cosmetics Act |
Schedule M / Revised Schedule M Compliance | Mandatory GMP standards covering premises, equipment, documentation, and quality systems |
WHO-GMP Certification (optional but valuable) | Required for export markets and most institutional/government tenders; held by fewer than 25% of current MSME manufacturers |
Udyam (MSME) & GST Registration | Standard business registrations enabling scheme eligibility and tax compliance |
Pollution Control Clearance | Required given effluent and chemical handling involved in drug manufacturing |
Environment/Fire NOC | Standard industrial safety clearances |
Getting your manufacturing license depends on your facility already meeting Schedule M design standards — so regulatory planning has to happen before, not after, your building is constructed.
What Investment Looks Like
Investment in a pharmaceutical manufacturing unit varies greatly depending on dosage form (tablets, capsules, syrups, injectables — sterile injectable facilities are significantly more expensive than oral solid dosage plants), production scale, and how much of your budget is allocated to compliance infrastructure versus machinery. Your project cost includes land and site development, civil construction built to cleanroom/GMP standards, manufacturing and packaging machinery, a quality control laboratory, and validation/documentation systems (which will increasingly include electronic batch manufacturing records under revised requirements).
Rather than quoting a single figure that does not reflect your specific dosage form or scale, it is important to understand that locating your unit within an established pharmaceutical cluster, SEZ, or bulk drug park can significantly reduce land costs and provide access to shared utility infrastructure, as well as potential state-level incentives tied to India’s PLI (Production-Linked Incentive) scheme for pharmaceuticals. Always base your actual investment plan on current, documented quotations from your architect, equipment suppliers, and a trained GMP consultant, as generic figures for this business fluctuate far too much to be appropriate for your unique project.
Financing Routes
Route | Suitability |
PLI Scheme for Pharmaceuticals | Best for larger manufacturers investing in genuine domestic value addition, including API manufacturing |
CGTMSE-backed MSME loan | Relevant for smaller-scale formulation units within MSME thresholds |
Standard bank term loan | The realistic route for most mid-to-large pharma manufacturing projects given typical investment scale |
State industrial incentives | Several states offer land, power, or capital subsidy incentives for pharma clusters and SEZs |
PMEGP and Mudra generally don’t fit this industry well, since even a modest compliant pharma facility typically exceeds their project cost ceilings once GMP-standard construction and validation costs are included.
Why Banks Look at Pharma Loan Applications Differently
Because your capacity to legally produce and sell is totally dependent on maintaining Schedule M compliance, banks looking for a pharma loan want to see that your project report explicitly covers your regulatory pathway, not simply your machinery and market plan. A financial plan that does not account for a realistic compliance and licensing timeframe, or that predicts revenue from the start without taking into account the time required for facility certification and license approval, is a common reason for application delays. Your DSCR (Debt Service Coverage Ratio) calculation, which most banks need to be at least about 1.25, must reflect this realistic ramp-up, usually supported by an adequately structured moratorium period rather than an immediate repayment assumption.
Common Mistakes New Entrants Make
- Designing a facility plan without consulting GMP or regulatory professionals.
- Ignoring compliance requirements during the initial planning phase.
- Underestimating the expenses of documentation and quality management systems.
- Treating Schedule M compliance as a one-time approval procedure.
- Failing to keep accurate batch records and production documents.
- Failure to plan for deviation management and change control systems.
- Begin operations without a long-term WHO-GMP certification strategy.
- Limited future export potential due to a lack of certificates.
- Ignoring the needs of institutional and wholesale buyers.
- Focusing solely on machinery while ignoring regulatory planning.
Frequently Asked Questions
Yes, Revised Schedule M compliance is required for pharmaceutical firms. Before continuing or initiating manufacturing operations, companies must comply with new quality and facility criteria as outlined in applicable regulations.
WHO-GMP accreditation is not required for all domestic producers, but it can boost exports and assist enterprises qualify for institutional buyers and regulated markets.
Entrepreneurs can apply for MSME loans and other financing solutions. A complete business strategy should cover license, compliance requirements, investment, and payback feasibility.
Yes, small businesses can enter this field with adequate preparation, but they must first establish appropriate infrastructure, technical competence, regulatory approvals, and quality control systems.
A pharmaceutical manufacturing facility often requires a medication manufacturing license, GST registration, business registration, and other permits, depending on the product type and applicable requirements.
Although WHO-GMP accreditation is not required for all domestic manufacturers, it does help enterprises get access to export markets and institutional purchasers while also improving trust.
Entrepreneurs can seek for business loans from banks and financial institutions. A complete project plan that includes investment, compliance, and financial estimates enhances loan evaluation.
The machinery used depends on the dosage form being prepared. Mixers, granulators, tablet machines, filling machines, packing machines, and quality testing equipment are all examples of commonly used equipment.